Cat.No：GM-87824AB
Product：Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
Cat.No：GM-87824AB
Product：Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
GM-87824AB-100 100μg
GM-87824AB-1mg 1mg
Expression System | CHO |
Purity | > 95% as determined by SDS-PAGE |
Aggregation | < 5% as determined by SEC-HPLC |
Drug-to-Antibody Ratio (DAR) | 8.0 |
Endotoxin | <1EU/mg |
Sterility | 0.22 μm Filtered |
Target | CD227 |
Clone | DS-3939 |
Alternative Names | ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X/ZD, PEM, PEMT, PUM |
Source/Isotype | Monoclonal Human IgG1, κ |
Application | Positive control of Cytotoxicity Assay |
Description | DS-3939 is an antibody-drug conjugate (ADC) candidate drug developed for targeted cancer therapy. It typically consists of a monoclonal antibody that specifically recognizes tumor-associated antigens, chemically linked to a cytotoxic payload. This type of drug aims to enhance antitumor activity and selectivity by precisely targeting tumor cells via the antibody, thereby reducing damage to normal cells. |
Formulation | 10 mM NaAc-HAc, pH5.0 |
Cat.No：GM-87824AB
Product：Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
GM-87824AB-100 100μg
GM-87824AB-1mg 1mg
Expression System | CHO |
Purity | > 95% as determined by SDS-PAGE |
Aggregation | < 5% as determined by SEC-HPLC |
Drug-to-Antibody Ratio (DAR) | 8.0 |
Endotoxin | <1EU/mg |
Sterility | 0.22 μm Filtered |
Target | CD227 |
Clone | DS-3939 |
Alternative Names | ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X/ZD, PEM, PEMT, PUM |
Source/Isotype | Monoclonal Human IgG1, κ |
Application | Positive control of Cytotoxicity Assay |
Description | DS-3939 is an antibody-drug conjugate (ADC) candidate drug developed for targeted cancer therapy. It typically consists of a monoclonal antibody that specifically recognizes tumor-associated antigens, chemically linked to a cytotoxic payload. This type of drug aims to enhance antitumor activity and selectivity by precisely targeting tumor cells via the antibody, thereby reducing damage to normal cells. |
Formulation | 10 mM NaAc-HAc, pH5.0 |
